Progesterone for the prevention of preterm birth: Indications, when to initiate, efficacy and safety

Therapeutics and Clinical Risk Management

Volumn 5, Issue 1, 2009, Pages 55-64

  How, Helen Y ^a   Sibai, Baha M ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

17 Alpha hydroxyprogesterone caproate; Preterm birth prevention

Indexed keywords

HYDROXYPROGESTERONE CAPROATE; PROGESTERONE;

ABDOMINAL PAIN; ACNE; ALLERGY; ARTHRALGIA; ASTHMA; BACKACHE; BLOATING; BREAST HYPERTROPHY; CLINICAL TRIAL; CONSTIPATION; CONTUSION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPAREUNIA; DYSURIA; FATIGUE; FEVER; FLU LIKE SYNDROME; GENITAL PRURITUS; HEADACHE; HUMAN; INJECTION SITE NODULE; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; LEG PAIN; LIBIDO; LONG TERM CARE; MASTALGIA; MOOD CHANGE; MYCOSIS; NAUSEA; NERVOUSNESS; NEWBORN MORBIDITY; NEWBORN MORTALITY; NOCTURIA; POLYURIA; PREMATURE LABOR; PRURITUS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SINUSITIS; SLEEP DISORDER; SOMNOLENCE; SPONTANEOUS ABORTION; STILLBIRTH; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA; VAGINA DISCHARGE; VOMITING;

EID: 77949480354     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: None     Document Type: Review

References (117)

1. Anon. Practice bulletin ACOG: clinical management guidelines for obstetrician gynecologist #31-assessment of risk factors for preterm birth. Obstet Gynecol. 2001;98:706-709.
2. Amon E. Preterm labor. In: Reece EA, Hobbins JC, editors. Medicine of the fetus and mothers. Philadelphia: Lippincott-Raven; 1999. p. 529-579.
3. Institute of Medicine of the National Academies. Preterm Birth: Causes, Consequences, and Prevention. Washington DC; National Academies Press; 2006. Accessed September 12, 2006. Available at: http://www. iom.edu/CMS/3740/25471/ 35813.aspx.
4. Tough SC, Newburn-Cook C, Johnston DW. Delayed childbearing and its impact on population rate changes in lower birth weight, multiple birth, and preterm delivery. Pediatrics. 2002;109(3):399-403.
5. Reynolds MM, Schieve LA, Martin JA, et al. Trends in multiple births conceived using assisted reproductive technology, united states, 1997-2000 Pediatrics. 2003;111(5):1159-1162.
6. Schieve, LA, Handler, A. Preterm delivery and perinatal death among black and white infants in a Chicago-area perinatal registry. Obstet Gynecol. 1996:88:356-363.
7. Martin JA, Hamilton BE, Ventura SJ. Births: preliminary data for 2000. Natl Vital Stat Rep. 2001;49:1-20.
8. Guyer B, Martin JA, MacDorman MF, et al. Annual summary of vital statistics-1996. Pediatrics. 1997;100:905-918.
9. March of Dimes Birth Defects Foundation. Available at: http://www. marchofdimes.com. Accessed July 11, 2005.
10. Gluckman PD, Hanson MA. Living with the past: evolution, development and patterns of disease. Science. 2004;305:1733-1736.
11. Tucker JM, Goldenberg RL, Davis RO, et al. Etiologies of preterm birth in an indigent population: Is prevention a logical expectation? Obstet Gynecol. 1991;77:343-347.
12. Goldenberg RL, Iams JD, Mercer BM, et al. The preterm prediction study: the value of new vs standard risk factors in predicting early and all spontaneous preterm births. NICHD MFMU Network. Am J Public Health. 1998;88:233-238.
13. Meis PJ, Ernest MM, Moore ML. Causes of low birth weight births in public and private patients. Am J Obstet Gynecol. 1987;956: 1165-1168.
14. Iams JD, Goldenberg RL, Meis PJ, et al. The length of the cervix and the risk of spontaneous premature delivery. N Engl J Med. 1996;334:562-572.
15. Tucker JM, Goldenberg RL, Moawad AH, et al. The preterm prediction study: effect of gestational age and cause of preterm birth on subsequent obstetric outcome. Am J Obstet Gynecol. 1999;181:1216-1221.
16. Goldenberg RL, et al. Vaginal fetal fi bronectin measurements from 8 to 22 weeks' gestation and subsequent spontaneous preterm birth. Am J Obstet Gynecol. 2000;183:469-475.
17. Carey JC, Klebanoff MA, Hauth JC, Hillier SL, et al. Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis. N Engl J Med. 2000;342:534-540.
18. McDonald HM, O'Loughlin JA, Vigneswaran R, et al. Impact of metronidazole therapy on preterm birth in women with bacterial vaginosis flora (Gardnerella vaginalis): a randomised, placebo controlled trial. Br J Obstet Gynaecol. 1997;104:1391-1397.
19. Guzman ER, Rosenberg JC, Houlihan C. Ivan J, et al. R. A new method using vaginal ultrasound and transfundal pressure to evaluate the asymptomatic incompetent cervix. Obstet Gynecol. 1994;83:248-252.
20. Owen J, Yost N, Berghella V, et al. For NICHD MFMU network. Mid-Trimester endovaginal sonography in women at high risk for spontaneous preterm birth. JAMA. 2001;286:1340-1348.
21. Vayssiere C, Favre R, Audibert F, et al; for the research group in obstetrics and gynecology. Cervical length and funneling at 22 and 27 weeks to predict spontaneous birth before 32 weeks in twin pregnancies: A French prospective multicenter study. Am J Obstet Gynecol. 2002;187:1596-1604.
22. Lazar P, Gueguen S, Dreyfus J, et al. Multicentered controlled trial of cervical cerclage in women at moderate risk of preterm delivery. Br J Obstet Gynaecol. 1984;91:731-735.
23. Dor J, Shaley J, Mashiach S, et al. Elective cervical suture of twin pregnancies diagnosed ultrasonically in the fi rst trimester following induced ovulation. Gynecol Obstet Investig. 1982;13:55-60.
24. Rush Rw, Isaacs S, McPherson K, et al. A randomized controlled trial of cervical cerclage in women at high risk for preterm delivery. Br J Obstet Gynaecol. 1984;91:724-730.
25. Grant AM. Cervical cerclage. In: Enkin MW, Keirse MJNC, Renfrew MJ, Neilson JP, editors. Pregnancy and childbirth module. Cochrane Database Syst Rev. Oxford: update software; 1994. Review No. 04135.
26. Dyson DC, Danbe KH, Bamber JA, et al. Monitoring women at risk for preterm labor. N Engl J Med. 1998;338:15-19.
27. Goldenberg RL, Rouse DJ. Prevention of premature birth. N Eng J Med. 1998;339:313-320.
28. Collaborative Group on Preterm Birth Prevention. Multicenter randomized controlled trial of a preterm birth prevention program. Am J Obstet Gynecol. 1993;169(2 Part 1):352-366.
29. Berkman ND, Thorp JM, Lohr KN, et al. Tocolytic treatment for the management of preterm labor: a review of the evidence. Am J Obstet Gynecol. 2003;188:1648-1659.
30. Olsen P, Laara E, Rantakillio P, et al. Epidemiology of preterm delivery in two birth cohorts with an interval of 20 years. Am J Epidemiol. 1995;142:1184-1193.
31. Morrison JJ, Rennie JM. Clinical, scientifi c and ethical aspects of fetal and neonatal care at extreme preterm periods of gestation. Br J Obstet Gynaecol. 1997;104:1341-1350.
32. McFarlane A, Cole S, Johnson A, et al. Epidemiology of birth before 28 weeks of gestation. Brit Med Bull. 1988;44:861-891.
33. Koupilova I, Vagero D, Leon DA, et al. Social variation in size at birth and preterm delivery in the Czech Republic and Sweden, 1989-1991. Paediatr Perinat Ep. 1998;12:7-24.
34. Mueller-Heubach E, Reddick D, Barnett B, et al. Preterm birth prevention: evaluation of a prospective controlled randomized trial. Am J Obstet Gynecol. 1989;160:1172-1178.
35. Collaborative Group on Preterm Birth Prevention. Multicenter randomized controlled trial of a preterm birth prevention program. Am J Obstet Gynecol. 1993;169:352-366.
36. McGrady GA, Sung JF, Rowley DL, et al. Preterm delivery and low birth weight among frist-born infants of black and white college graduates. Am J Epidemiol. 1992;136:266-276.
37. Mattison DR, Damus K, Fiore E, et al. Preterm delivery: a public health perspective. Paediatr Perinat Ep. 2001;15:7-16.
38. Ananth CV, Misra DP, Demissie K, et al. Rates of preterm delivery among black women and white women in the United States over two decades: an age-period-cohort analysis. Am J Epidemiol. 2001;154:657-665.
39. Vega WA, Kolody B, Hwang J, et al. Perinatal drug use among immigrant and native-born latinas. Subst Use Misuse. 1997;32:43-62.
40. Amaro H, Whitaker R, Coffman G, et al. Acculturation and marijuana and cocaine use: Findings from HHANES 1982-84. Am J Public Health. 1990;80 Suppl:54-60.
41. Vega WA, Alderete E, Kolody B, et al. Illicit drug use among Mexicans and Mexican Americans in California: the effects of gender and acculturation. Addiction. 1998;93:1839-1850.
42. Ventura SJ, Taffel SM. Childbearing characteristics of US -and foreign-born hispanic mothers. Public Health Rep. 1985;100:647-652.
43. Guendelman S, English PB. Effect of United States residence on birth outcomes among Mexican immigrants: An exploratory study. Am J Epidemiol. 1995;142(Suppl)S30-S38.
44. Collins JW, Martin CR. Relation of traditional risk factors to intrauterine growth retardation among United States-born and foreign-born Mexican Americans in Chicago. Ethnicity Dis. 1998;8:21-25.
45. Scribner R, Dwyer JH. Acculturation and low birthweight among Latinos in the Hipanic HANES. Am J Public Health. 1989;79:1263-1267.
46. Collins JW, Shay DK. Prevalence of low birth weight among Hispanic infants with United States-born and foreign-born mothers: The effect of urban poverty. Am J Epidemiol. 1994;139:184-192.
47. Main DM, Richardson DK, Hadley CB, et al. Controlled trial of a preterm labor detection program: effi cacy and costs. Obstet Gynecol. 1989;74:873-877.
48. Fangman JJ, Mark PM, Pratt L, et al. Prematurity prevention programs: An analysis of successes and failures. Am J Obstet Gynecol. 1994;170:744-750.
49. Creasy RK, Gummer BA, Liggins GC. System for predicting spontaneous preterm birth. Obstet Gynecol. 1980;55:692-695.
50. Savitz DA, Blackmore CA, Thorp JM. Epidemiologic characteristics of preterm delivery: Etiologic heterogeneity. Am J Obstet Gynecol. 1991;164:467-471.
51. Migone A, Emanuel I, Mueller B, et al. Gestational duration and birthweight in white, black and mixed-race babies. Paediatr Perinat Epidemiol. 1991;5:378-391.
52. MacGregor JA, French JI, Jones W, et al. Bacterial vaginosis is associated with prematurity and vaginal fl uid mucinase and sialidase: Results of controlled trial of clindamycin cream. Am J Obstet Gynecol. 1994;170:1048-1060.
53. Mclean M, Walters WAW, Smith R. Prediction and early diagnosis of preterm labor: A critical review. Obstet Gynecol Surv. 1993;48:209-225.
54. Frederick J, Anderson ABM. Factors associated with spontaneous preterm birth. Br J Obstet Gynaecol. 1976;83:342-350.
55. Carr-Hill RA, Hall M. The repetition of spontaneous preterm labor. Br J Obstet Gynaecol. 1985;92:921-928.
56. Bakketeig LS, Hoffman HJ, Harley EE. The tendency to repeat gestational age and birth weight in successive births. Am J Obstet Gynecol. 1979;135:1086-1103.
57. Wildschut HIJ, Lumey LH, Lunt PW. Is Preterm delivery genetically determined? Paediatr Perinat Epidemiol. 1991;5:363-372.
58. Johnstone F, Inglis L. Familial trend in low birthweight. BMJ. 1974;3:659-661.
59. Khoury MJ, Cohen BH. Genetic heterogeneity of prematurity and intrauterine growth retardation: Clues from the old order Amish. Am J Obstet Gynecol. 1987;157:400-410.
60. Klebanoff MA, Meirik O, Berendes HW. Second-generation consequences of small for dates births. Pediatrics. 1989;84:343-347.
61. Magnus P, Bakketeig LS, Skjaerven R. Correlations of birth weight and gestational age across generations. Ann Hum Biol. 1993;20:231-238. 60a.
62. Strauss JF. Unravelling the genetics of complex disorders of reproduction. In: Coutinho EM, Spinola P, editors. Reproductive medicine: a millennium review. New York: Parthenon; 199. p. 284-287.
63. Kornman KS, Crane A, Wang HY, et al. The interleukin-1 genotype as a severity factor in adult periodontal disease. J Clin Periodontol. 1997;24:72-77.
64. Hurme M, Santtila S. IL-1 receptor antagonist (IL-1Ra) plasma levels are co-ordinately regulated by both IL-Ra and IL-1beta genes. Eur J Immunol. 1998;28:2598-2602.
65. Johnstone F, Inglis L. Familial trends in low birth weigh. BMJ. 1974;3:659-661.
66. Porter TF, Fraser AM, Hunter CY, et al. The risk of preterm birth across generations. Obstet Gynecol. 1997;90:63-67.
67. Carr-Hill RA, Hall MH. The repetition of spontaneous preterm labour. Br J Obstet Gynecol. 1985;92:921-928.
68. Bakketeig LS, Hoffman HJ, Harley EE. The tendency to repeat gestational age and birth weight in successive births. Am J Obstet Gynecol. 1979;135:1086-1103.
69. Vatten LJ, Skjaerven R. Effects on pregnancy outcome of changing partner between fi rst two births: prospective population study. BMJ. 2003;327:1138-1141.
70. Li DK. Changing paternity and the risk of preterm delivery in the subsequent pregnancies. Epidemiology. 1999;10:148-152.
71. Basso O, Olsen J, Christensen K. Low birth weight and prematurity in relation to paternal factors: a study of recurrence. Int J Epidemiol. 1999;28:695-700.
72. Amon E. Preterm Labor. In: Reece EA, Hobbins JC, editors. Medicine of the fetus and mothers. Philadelphia: Lippincott-Raven: 1999;p. 1529-79.
73. Fuchs F, Stakeman G. Treatment of threatened premature labor with large does of progesterone. Am J Obstet Gynecol. 1960;79:172.
74. Fuchs AR, Fuchs F. Endocrinology of human parturition: a review. Br J Obstet Gynaecol. 1984;91:948-967.
75. Csapo AI, The "see-saw" theory of parturition. In: O'Connor M, Knight J, (eds.) The fetus and birth. New York: Elsevier, 1977;p 159-210.
76. Liggins GC, Thorburn GD. Initiation of parturition. In: Lamming GE, (ed.) Marshall's physiology of reproduction. London: Chapman and Hall, 1994;p. 863-1002.
77. Flint APP, Anderson ABM, Steele PA, et al. The mechanisms by with foetal cortiosol controls the onset of parturition in the sheep. Biochem Soc Trans. 1975;3:1189-1194.
78. Lye SJ, Porter DG, Demonstration that progesterone "blocks" uterine activity in the ewe in vivo by a direct action on the myometrium. J Reprod Fertil. 1978;52:87-94.
79. Tulchinsky D, Hobel CJ, Yeager E, et al. Plasma estrone, estradiol, estriol, progesterone, and 17-hydroxyprogseterone in human pregnancy. I. Normal pregnancy. Am J Obstet Gynecol. 1972;112:1095-1100.
80. Walsh SW, Stanczyk FZ, Novy MJ. Daily hormonal changes in the maternal, fetal and amniotic fl uid compartments before parturition in a primate species. J Clin Endocrinol Metab. 1984;58:629-639.
81. Avrech OM, Golan A, Weinraub Z, et al. Mifepristone (RU486) alone or in combination with prostaglandin analogue for termination of early pregnancy: A review. Fertil Steril. 1991;56:385-393.
82. Haluska GJ, Novy MJ. Hormonal modulation of uterine activity during primate parturition. Semin Reprod Endocrinol. 1993;11:261-271.
83. Selinger M, MacKenzie IZ, Gillmer MD, et al. Progesterone inhibition in mid-trimester termination of pregnancy: Physiological and clinical effects. Br J Obstet Gynaecol. 1987;94:218-222.
84. Haluska GJ, Cook MJ, Novy MJ. Inhibition and augmentation of progesterone production during pregnancy: effects of parturition and rhesus monkeys. Am J Obstet Gynecol. 1997;176:682-691.
85. Lye S. The initiation and inhibition of labour-toward a molecular understanding. Semin Reprod Endocrinol. 1994;12:284-294.
86. Westphal U, Stroupe SD, Cheng SL. Progesterone binding to serum proteins. Ann NY Acad Sci. 1977;286:10-28.
87. McGarrigle HH, Lachelin GC. Increasing saliva (free) oestriol to progesterone ration in late pregnancy: a role for oestriol in initiating spontaneous labor in man? Br Med J Clin Res Ed. 1984;289:457-459.
88. Mitchell BF, Wong S. Changes in 17 B, 20-alpha-hydroxysteroid dehydrogenase activity supporting an increase in the estrogen/ progesterone ratio of human fetal membranes at parturition. Am J Obstet Gynecol. 1993;68:1377-1385.
89. Progesterone therapy. Progesterone ... what is it? Accessed December 21, 2006. Available at: http//:www.progesteronetherapy.com/.
90. Murray JL, Natural progesterone: what role in women's health care? Women's Health Primary Care. 1998;1:671-687.
91. Onsrud M, Paus E, Haug E, et al. Intraumuscular administration of hydroxyprogesterone caproate in patients with endometrial carcinoma. Pharmacokinetics and effects on adrenal function. Acta Obstet Gynecol Scand. 1985;64:519-523.
92. von Eye Corleta H, Capp E, Ferreira MBC. Pharmacokinetics of natural progesterone vaginal suppository. Gynecol Obstet Invest. 2004;58:105-108.
93. Di Renzo GC, Mattei A, Gojnic M, et al. Progesterone and pregnancy. Curr Opin Obstet Gynecol. 2005;17:598-600.
94. Penzias AS, Alper MM. Luteal support with vaginal micronized progesterone gel in assisted reproduction. Reprod Biomed Online. 2003;6:287-295.
95. Posaci C, Smitz J, Camus M, et al. Progesterone for the luteal support of assisted reproductive technologies: clinical options. Human Reprod. 2000;15(suppl 1):129-148.
96. LeVine L. Habitual abortion: a controlled clinical study of pregestational therapy. West J Surg Obstet Gynecol. 1964;72:3036.
97. Papiernik E. Double blind study of an agent to prevent pre-term delivery among women at increased risk. Schering ed. Series 4, 1970; p. 65-68.
98. Johnson JWC, Austin KL, Jones GS, et al. Efficacy of 17α- hydroxyprogesterone caproate in the prevention of premature labor. N Engl J Med. 1975;293:675-680.
99. Yemini M, Borenstein R, Dreazen E, et al. Prevention of premature labor by 17 alphahydroxyprogesterone caproate. Am J Obstet Gynecol. 1985;151:574-577.
100. Hartikainen-Sorri A-L, Kauppila A, Tuimala R. Inefficacy of 17α-hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstet Gynecol. 1980;56:692-695.
101. Hauth JC, Gilstrap LC III, Brekken AL, et al. The effect of 17 alphahydroxyprogestrone caproate on pregnancy outcome in an active-duty military population. Am J Obstet Gynecol. 1983;146:187-190.
102. Keirse MJNC. Progesterone administration in pregnancy may prevent preterm delivery. Br J Obstet Gynaecol. 1990;97:149-154.
103. da Fonseca E, Bittar RE, Carvalho MHB, et al. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous Preterm birth in women at increased risk: A randomized placebo-controlled double-blind study. Am J Obstet Gynecol. 2003;188:419-424.
104. Meis PJ, Klebanoff M, Thom E, et al. NICHD MFMU Network. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med. 2003;348(24):2379-2385.
105. Spong CY, Meis PJ, Thom EA, et al. Progesterone for prevention of recurrent preterm birth: Impact of gestational age at previous delivery. Am J Obstet Gynecol. 2005;193:1127-1131.
106. O'Brien JM, Adair CD, Lewis, DF, et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: Primary results from a randomized, double blind, placebo controlled trial. Ultrasound Obstet Gynecol. 2007;30:687-696.
107. Rouse D, Caritis S, Peaceman AM, et al. NICHD MFMU Network. A trial of 17-Alpha-hydorxyprogesterone Caproate to prevent prematurity in Twins. N Engl J Med. 2007;357:454-461.
108. da Fonseca EB, Celik E, Paire M, et al. for the Fetal Medicine Foundation, Second Trimester Screening Group. Progesterone and the Risk of Preterm Birth Among Women with a Short Cervix. N Engl J Med. 2007;357:462-469.
109. Rebarber A, Ferrara LA, Hanley ML, et al. Increased recurrence of preterm delivery with early cessation of 17-alpha-hydroxyprogeterone caproate. Am J Obstet Gynecol. 2007;196:224.e1-24.e4.
110. How HY, Barton J, Istwan N, et al. Prophylaxis with 17 Alphahydroxyprogesterone Caproate for Prevention of Recurrent Preterm Delivery: Does Gestational Age at Initiation of Treatment Matter? Am J Obstet Gynecol. 2007;197:260.e1-260.e4.
111. FDA issues NDA 21-945. Proposed Indication. "Gestiva is indicated for the prevention of preterm birth in ... www.fda.gov/ohms/dockets/ ac/06/briefi ng/2006-4227B1-02-01-FDA-backgroung.pdf.
112. Heinonen OP, Slone D, Shapiro S. Birth defects and Drugs in Pregnancy. Littleton, Mass: PSG Publishing; 1977.
113. Crossley KJ, Nicol MB, Hisrst JJ, et al. Suppression of arousal by progesterone in fetal sheep. Reprod Fertil Dev. 1997;9:767-773.
114. Nicol MB, Hirst JJ, Walker D, et al. Effect of alteration of maternal plasma progesterone concentration on fetal behavioural state during late gestation. J Endocrinol. 1997;152:379-386.
115. Northen AT, Norman GS, Anderson K, et al. for NICHD MFMU Network. Follow-up of children exposed to 17 Aalpha-hydroxyprogesterone caproate compared with placebo. Obstet Gynecol. 2007;110:865-872.
116. Brancazio LR, Murtha AP, Heine RP. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med. 2003;349:1987-1988.
117. American College of Obstetricians and Gynecologists. ACOG committee opinion. Use of progesterone to reduce preterm birth. Obstet Gynecol. 2003;102:1115-1116.